A clinical trial update dated August 17, 2026 reports that a Phase 2 study of oral PHA-022121 has been terminated. The trial, registered as NCT05047185, was titled "Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II." It was designed to evaluate dosing for prophylaxis against angioedema attacks in patients with hereditary angioedema type I or type II. The study status is listed as terminated, and no results or outcome data are included in this update. PHA-022121 relates to bradykinin, which remains classified as an unapproved compound used in research contexts. No reason for termination, efficacy findings, or safety conclusions are provided in the available event data. This brief reflects only the status change recorded for this trial registration and does not characterize the compound's safety or effectiveness. Readers seeking further detail on trial design or history can consult the official registration listing. For general background on bradykinin and its research context, refer to the compound overview.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT05047185"]